Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors

Jean-Jacques Kiladjian • 16 May 2022
General Updates
Myelofibrosis Myeloproliferative Neoplasms Imetelstat Navitoclax Navtemadlin Parsaclisib Pelabresib Ruxolitinib

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an overview of agents that are currently being evaluated in patients with myelofibrosis (MF) who have failed treatment with JAK inhibitors, including parsaclisib, pelabresib, navitoclax, imetelstat, and navtedmadlin. This interview took place virtually.

Disclosures

Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.

More from Jean-Jacques Kiladjian

2:31
The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian • 9 Oct 2023
4:35
The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian • 13 Jun 2023
2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023
2:09
Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligible
Jean-Jacques Kiladjian • 26 Apr 2023

Related Videos

1:25
Highlights on myelofibrosis from ASH
Claire Harrison • 21 Dec 2018
3:07
Ruxolitinib plus azacitidine for myelofibrosis
Naval Daver • 18 Dec 2018
1:06
Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors
Ivan Moiseev • 1 Sep 2020
2:39
Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide
Jean-Jacques Kiladjian • 6 Dec 2018
The content of VJHemOnc is intended for healthcare professionals